NCT06435312 2026-03-13
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
Clinical Trials
7 trialsNCT06055959 2026-02-27
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT07215949 2026-02-23
Zilucoplan for Severe gMG Exacerbations
Ohio State University
Phase 3 Recruiting
NCT06471361 2025-09-26
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT05514873 2025-09-03
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB Pharma
Phase 3 Completed
NCT04115293 2025-07-16
RAISE
UCB Pharma
Phase 3 Completed
NCT03315130 2022-07-27
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
UCB Pharma
Phase 2 Completed